<DOC>
	<DOCNO>NCT00873275</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , ursodiol , oxaliplatin , leucovorin , fluorouracil , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Bevacizumab may also stop growth colorectal cancer block blood flow tumor . Giving ursodiol together leucovorin calcium , fluorouracil , oxaliplatin , bevacizumab may effective treatment colorectal cancer . PURPOSE : This phase I trial study side effect best dose ursodiol give together combination chemotherapy bevacizumab treat patient stage IV colorectal cancer .</brief_summary>
	<brief_title>Ursodiol , Combination Chemotherapy , Bevacizumab Treating Patients With Stage IV Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine active dose and/or maximum tolerate dose ursodiol give combination fluorouracil , leucovorin calcium , oxaliplatin ( FOLFOX regimen ) , bevacizumab patient metastatic colorectal cancer . - To determine pharmacokinetics ursodiol give regimen . Secondary - To determine systemic metabolic effect ursodiol activation nuclear receptor farnesoid X receptor ( FXR ) glucose lipid metabolism . - To develop assay detect ursodiol activation FXR . - To identify evaluate potential serum biomarkers FXR activation . - To determine gene regulate activation FXR target tissue . OUTLINE : This dose-escalation study ursodiol . Patients receive oral ursodiol twice daily day 1-28 ( day -6 28 course 1 ) , leucovorin calcium intravenously ( IV ) 2 hour day 1 15 , fluorouracil IV 46 hour day 1-2 15-16 , oxaliplatin IV 2 hour bevacizumab IV 30-90 minute day 1 15 . Courses repeat every 4 week absence disease progression unacceptable toxicity . Blood sample collect periodically pharmacokinetic study . Samples also analyze role nuclear receptor farnesoid X receptor ( FXR ) glucose uptake metabolism use PET scan imaging , oral glucose tolerance test , HbA1c level ; effect FXR activation lipid metabolism ; marker response FXR activation via western blot . Available formalin-fixed paraffin-embedded tumor tissue block analyze FXR express via IHC ; expression know FXR target gene via RNA analysis real-time PCR ; expression gene involve glucose metabolism .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Ursodeoxycholic Acid</mesh_term>
	<criteria>Patients advance , biopsy proven metastatic colorectal cancer Karnofsky Performance Status &gt; = 80 Prior therapy complete least 3 week protocol treatment initiation recovery sideeffects Serum albumin prealbumin within normal limit Alanine aminotransferase ( ALT ) within 3 x upper limit normal Alkaline phosphatase within 3 x upper limit normal Serum bilirubin within normal limit Absolute neutrophil count &gt; = 1500/ul Serum creatinine within 1.5 x upper limit normal Ability understand sign institutional review board ( IRB ) approve informed consent Ability use appropriate contraception evidence pregnancy female patient reproductive potential Significant medical psychiatric condition would make treatment unsafe Use systemic steroid use within 7 day start trial Nursing woman Patients unable comply protocol related study follow Weight loss great 10 % last 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
</DOC>